Gene Delivery Using Viral Vectors - Challenges in Delivery of Therapeutic Genomics and Proteomics - page 261

[73] Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH.
ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and
antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat
Med 1997;3:639-45.
[74] Fueyo J, Gomez-Manzano C, Alemany R, Lee PS, McDonnell TJ, Mitlianga P, et al.
A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect
in vivo . Oncogene 2000;19:2-12.
[75] Tai YT, Strobel T, Kufe D, Cannistra SA. In vivo cytotoxicity of ovarian cancer cells
through tumor-selective expression of the BAX gene. Cancer Res 1999;59:2121-6.
[76] Onyx plans phase III trial of ONYX-015 for head & neck cancer. Oncologist 1999;4:432.
[77] Wildner O, Blaese RM, Morris JC. Therapy of colon cancer with oncolytic adenovi-
rus is enhanced by the addition of herpes simplex virus-thymidine kinase. Cancer Res
1999;59:410-3.
[78] Oliver W, John CM. Therapy of peritoneal carcinomatosis from colon cancer with onco-
lytic adenoviruses. J Gene Med 2000;2:353-60.
[79] Kagawa S, Pearson SA, Ji L, Xu K, McDonnell TJ, Swishe SG, et al. A binary adeno-
viral vector system for expressing high levels of the proapoptotic gene bax. Gene Ther
2000;7:75-9.
[80] Wildner O, Morris JC, Vahanian NN, Ford H Jr., Ramsey WJ, Blaese RM. Adenoviral
vectors capable of replication improve the efficacy of HSV tk/GCV suicide gene therapy
of cancer. Gene Ther 1999;6:57-62.
[81] Van Kampen KR, Shi Z, Gao P, Zhang J, Foster KW, Chen DT, et al. Safety and immu-
nogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans.
Vaccine 2005;23:1029-36.
[82] Ganly I, Kirn D, Eckhardt SG, Rodriguez GI, Soutar DS, Otto R, et al. A phase I study of
Onyx- 015, an E1B attenuated adenovirus, administered intratumorally to patients with
recurrent head and neck cancer. Clin Cancer Res 2000;6:798-806.
[83] Kirn D, Hermiston T, McCormick F. ONYX-015: clinical data are encouraging. Nat Med
1998;4:1341-2.
[84] Rothmann T, Hengstermann A, Whitaker NJ, Scheffner M, zur Hausen H. Replication
of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor
cells. J Virol 1998;72:9470-8.
[85] Shanley JD, Wu CA. Mucosal immunization with a replication-deficient adenovirus vec-
tor expressing murine cytomegalovirus glycoprotein B induces mucosal and systemic
immunity. Vaccine 2003;21:2632-42.
[86] Grieger JC, Samulski RJ. Adeno-associated virus as a gene therapy vector: vector develop-
ment, production and clinical applications. Adv Biochem Eng/Biotechnol 2005;99:119-45.
[87] Surosky RT, Urabe M, Godwin SG. Adeno-associated virus rep proteins target DNA
sequences to a unique locus in the human genome. J Virol 1997;71:7951-9.
[88] Chirmule N, Propert K, Magosin S, Qian Y, Qian R, Wilson J. Immune responses to ade-
novirus and adeno-associated virus in humans. Gene Ther 1999;6:1574-83.
[89] Hernandez YJ, Wang J, Kearns WG, Loiler S, Poirier A, Flotte TR. Latent adeno-
associated virus infection elicits humoral but not cell-mediated immune responses in a
nonhuman primate model. J Virol 1999;73:8549-58.
[90] Ponnazhagan S, Mukherjee P, Yoder MC. Adeno-associated virus 2-mediated gene
transfer in vivo : organ-tropism and expression of transduced sequences in mice. Gene
1997;190:203-10.
[91] Carter BJ. Adeno-associated virus vectors in clinical trials. Hum Gene Ther
2005;16:541-50.